did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

We're the #1 textbook rental company. Let us show you why.

9781607509783

Biomarkers for Ovarian Cancer: New Technologies and Targets to Address Persistently Unmet Needs

by
  • ISBN13:

    9781607509783

  • ISBN10:

    1607509784

  • Edition: 1st
  • Format: Paperback
  • Copyright: 2011-12-01
  • Publisher: IOS PRESS INC

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

Purchase Benefits

List Price: $167.00 Save up to $61.79
  • Rent Book $105.21
    Add to Cart Free Shipping Icon Free Shipping

    TERM
    PRICE
    DUE
    IN STOCK USUALLY SHIPS IN 24 HOURS
    *This item is part of an exclusive publisher rental program and requires an additional convenience fee. This fee will be reflected in the shopping cart.

Supplemental Materials

What is included with this book?

Supplemental Materials

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Excerpts

Cytoreductive surgery and combination chemotherapy have improved 5 year survival for patients with ovarian cancer, but only 30% are cured due to detection at a late stage and the persistence of dormant, drug resistant cancer cells. Biomarkers could aid in early detection and in personalizing therapy to identify patients who would benefit from conventional or novel targeted drugs. Epithelial ovarian cancers are remarkably heterogeneous, differing in grade, histotype, invasiveness and proliferative index. Low grade Type I serous cancers are associated with mutations of Ras and Raf, but not p53, whereas high grade Type II serous ovarian cancers nearly all have p53 mutations, but rarely mutations of Ras or Raf. An effective screening strategy must detect both types of serous ovarian cancer, as well as the non-serous histotypes. CA125 is expressed by approximately 80% of ovarian cancers, but is elevated in serum at the time of conventional diagnosis in only 50-60% of patients with stage I lesions. Papers appearing in this issue deal with several technologies and a variety of compounds that could provide serum biomarkers which complement or surpass CA125 for early detection. Among these are proteomic techniques, multiplex assays, antibody arrays, glycans, methylated promoters, miRNAs and exosomes. Improved imaging strategies are also considered. To personalize therapy with conventional or targeted drugs, prognostic and predictive biomarkers can be used to match particular cancers with particular agents or modalities. Given the expense of anti-vascular therapy, biomarkers with a high negative predictive value would be particularly helpful. Potential biomarkers have been found in endothelial cells from ovarian cancers associated vessels. IOS Press is an international science, technical and medical publisher of high-quality books for academics, scientists, and professionals in all fields.
Some of the areas we publish in:
-Biomedicine
-Oncology
-Artificial intelligence
-Databases and information systems
-Maritime engineering
-Nanotechnology
-Geoengineering
-All aspects of physics
-E-governance
-E-commerce
-The knowledge economy
-Urban studies
-Arms control
-Understanding and responding to terrorism
-Medical informatics
-Computer Sciences

Rewards Program